NEO - Earnings announcements

First quarter total revenue increased 11% YoY to $187 million; Clinical revenue grew 14%, including NGS growth of 26%; Company announces increase in full-year 2026 revenue guidance to a range of $797-$803 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first quarter results for the period ended March 31, 2026. First Quarter 2026 Financial Highlights As Compared To First Quarter 2025   Consolidated revenue increased 11% to a first quarter record $187 million, driven by Clinical revenue growth of 14%   Net loss decreased 34% to $17 million

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Tuesday, April 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. Beginning with Q1 2026, NeoGenomics will hold quarterly results calls after market close to allow time for follow-up discussions before the next trading day. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast

Full-year revenue increased 10% to $727 million; Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition; Successfully resolved RaDaR ST patent litigation NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its fourth-quarter and full-year results for the period ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights   Fourth quarter consolidated revenue increased 11% to $190 million; Full-year consolidated revenue increased 10% to $727 million Fourth quarter net loss decreased 36% to $10 million; Full-year net loss increased 37

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 5

Third quarter total revenue increased 12% YoY to $188 million Clinical revenue grew 18%, or 15% excluding the Pathline acquisition NGS revenue increased 24% YoY and now accounts for nearly one-third of clinical revenue Re-affirming full-year guidance for revenue, net loss and adjusted EBITDA NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third quarter results for the period ended September 30, 2025. Third Quarter 2025 Highlights As Compared To Third Quarter 2024   Consolidated revenue increased 12% to a record $188 million, driven by Clinical revenue growth of 18%

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, October 28, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domesti

Second Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. Second Quarter 2025 Highlights As Compared To Second Quarter 2024   Consolidated revenue increased 10% to record $181 million   Net loss increased 142% to $45 million including $20 million of impairment charges   Adjusted EBITDA remained relatively flat at positive $11 million  

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic)

Consolidated Revenue Increased 8% to $168 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights As Compared To First Quarter 2024 Consolidated revenue increased 8% to $168 million Net loss decreased 4% to $26 million Adjusted EBITDA increased 102% to positive $7 million "Our business is off to a solid start in 2025 with our team delivering a record number of results to patients in the first quarter and improving our adjusted EBITDA by over 100% from prior year," said Ton

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) o

Full Year Revenue Increased 12% to $661 million; Ninth Consecutive Quarter of Double-Digit Revenue Growth NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its fourth-quarter and full year results for the period ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Fourth quarter consolidated revenue increased 11% to $172 million; Full year consolidated revenue increased 12% to $661 million Fourth quarter net loss increased 7% to $15 million; Full year net loss decreased 11% to $79 million Fourth quarter adjusted EBITDA increased 27% to positive $12 million; Full year adjusted EBITDA increased 1,036% to

NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Tuesday, February 18, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (i

Adjusted EBITDA Improves 305%; Fifth Consecutive Quarter of Positive Adjusted EBITDA; Increasing FY Guidance to $37-$40 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2024. Third Quarter 2024 Highlights As Compared To Third Quarter 2023   Consolidated revenue increased 10% to $168 million Clinical Services revenue increased 14% to $146 million Advanced Diagnostics revenue decreased 10% to $22 million Net loss decreased 4% to $18 million Adjusted EBITDA increased 305% to positive $13 million "We delivered a strong third quarter, again gro

NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior

Company will host business update call on Sept. 24, 2024, at 8:30 a.m. ET NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today issued the following statement in response to inquiries: NeoGenomics has cleared the feasibility stage with a new version of its RaDaR® technology and has resolved litigation with Natera regarding RaDaR 1.0. The Company will host a business update conference call and webcast on Tuesday, Sept. 24, 2024, beginning at 8:30 a.m. Eastern Time. The accelerated progress of the new RaDaR technology provided the Company the opportunity to negotiate a resolution with Natera as to RaDaR 1.0. The settlement, while confidential, is not material t

Second Quarter Revenue Increased 12% to $165 Million Raising Revenue Guidance $655 to $667 Million and Adjusted EBITDA to $33 to $37 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2024. Second Quarter 2024 Highlights As Compared To Second Quarter 2023   Consolidated revenue increased 12% to $165 million Clinical Services revenue increased 15% to $141 million Advanced Diagnostics revenue decreased 3% to $23 million Net loss decreased 23% to $19 million Adjusted EBITDA increased 630% to positive $11 million "The second quart

NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior

First Quarter Revenue Increased 14% to $156 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024. Highlights   Consolidated revenue increased 14% to $156 million Clinical Services revenue increased 17% to $135 million Advanced Diagnostics revenue decreased 3% to $22 million Net loss decreased 12% to $27 million Adjusted EBITDA was positive $3 million, an increase of 149% or $11 million "NeoGenomics had a strong start to 2024, with first quarter revenue growth of 14% yea

NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its first quarter 2024 financial results on Tuesday, April 30, 2024. Company management will host a webcast and conference call that morning at 8:30 a.m. Eastern Time to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (877) 545-0523 (domestic) or (973) 528-0016 (international) at least five minutes prior to the call. The part

Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023. Highlights Fourth quarter consolidated revenue increased 12% to $156 million; Full year consolidated revenue increased 16% to $592 million Fourth quarter Clinical Services revenue increased 20% to $130 million; Full year Clinical Services revenue increased 18% to $496 million Fourth quarter Advanced Diagnostics revenue decreased 17% to $25 million; Full year

NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024. Company management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to

Third Quarter Revenue Increased 18% to $152 MillionFORT MYERS, FL / ACCESSWIRE / November 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2023 as compared to September 30, 2022.Third Quarter 2023 HighlightsQ3 2023 ResultsConsolidated revenue increased 18% to $152 millionClinical Services revenue increased 20% to $128 millionAdvanced Diagnostics revenue increased 8% to $24 millionNet loss decreased 50% to $19 millionAdjusted EBITDA increased 129% to positive $3 millionRaised Full-Year 2023 GuidanceRaised revenue guidance to a range of $585 million - $592 million,

FT. MYERS, FL / ACCESSWIRE / October 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its third quarter 2023 financial results on Monday, November 6, 2023. Company management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call.To access the live call via telephone, dial (888) 506-0062 (domestic) or (973)

Second Quarter Revenue Increased 18% to $147 MillionFORT MYERS, FL / ACCESSWIRE / August 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2023 as compared to June 30, 2022.Highlights Consolidated revenue increased 18% to $147 million Clinical Services revenue increased 17% to $123 million Advanced Diagnostics revenue increased 22% to $24 million Net loss decreased 31% to $24 million Adjusted EBITDA increased 87% to negative $2 million "Our team delivered another excellent quarter with double-digit growth in both our Clinical Services and Advanced Diagnostics business

FT. MYERS, FL / ACCESSWIRE / July 18, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023. Company management will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call.To access the live call via telephone, dial (888) 506-0062 (domestic) and (973) 5

First Quarter Revenue Increased 17% to $137 MillionFORT MYERS, FL / ACCESSWIRE / May 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its first-quarter results for the period ended March 31, 2023.HighlightsConsolidated revenue increased 17% to $137 millionClinical Services revenue increased 16% to $115 millionPharma Services revenue increased 22% to $22 million"Our business continued the momentum we saw in the fourth quarter of last year into the first quarter with accelerated double-digit revenue growth in both the Clinical and Pharma businesses," said Chri

FT. MYERS, FL / ACCESSWIRE / April 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that it will release its first quarter 2023 financial results on Monday, May 8, 2023. Along with the release, NeoGenomics will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.To access the live call via telephone, interested investors should dial (888) 506-0062 (domestic) and (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 357448.The live webcast may be accessed by visit

Fourth Quarter Revenue Increased 10% to $139 million;Full Year Revenue Increased 5% to $510 millionFORT MYERS, FL / ACCESSWIRE / February 23, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company") , a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2022 results for the period ended December 31, 2022.HighlightsFourth quarter consolidated revenue increased 10% to $139 million; Full year consolidated revenue increased 5% to $510 millionFourth quarter Clinical Services revenue increased 4% to $108 million; Full year Clinical Services revenue increased 4% to $419 millionFourth quarter Pharma Services revenue increased 41% to

FT. MYERS, FL / ACCESSWIRE / February 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that it plans to release its fourth quarter and full year 2022, financial results on Thursday, February 23, 2023.The Company has scheduled a webcast and conference call to discuss their fourth quarter and full year 2022 results on Thursday, February 23, 2023 at 8:30 AM EDT. Interested investors should dial (888) 506-0062 (domestic) and (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 647216. A replay of the conference call will be available unti

Third Quarter Revenue Increased 6% to $129 MillionFORT MYERS, FL / ACCESSWIRE / November 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its third-quarter results for the period ended September 30, 2022.HighlightsConsolidated revenue increased 6% to $129 millionClinical Services revenue increased 4% to $106 millionPharma Services revenue increased 18% to $23 million"I am pleased by the progress that we made as a business during the third quarter, including improvements in turn-around time, revenue growth and gross margin. While we still have substantial opp

FT. MYERS, FL / ACCESSWIRE / October 13, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its third quarter 2022, financial results on Tuesday, November 8, 2022.The Company has scheduled a webcast and conference call to discuss their third quarter 2022 results on Tuesday, November 8, 2022 at 8:30 AM EDT. Interested investors should dial (888) 506-0062 (domestic) and (973) 528-00117 (international) at least five minutes prior to the call. The participant access code provided for this call is 188444. A replay of the conference call will be available until 8:30 AM EDT on No

Second-Quarter 2022 Results and HighlightsConsolidated revenue increased 3% to $125 millionClinical Services revenue increased 4% to $106 millionPharma Services revenue decreased 4% to $19 millionChris Smith appointed CEO effective August 15, 2022FORT MYERS, FL / ACCESSWIRE / August 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its second-quarter results for the period ended June 30, 2022."During a challenging time in our business, our people have rallied together as we welcome talented new leaders, embark on an enterprise wide performance improvement pla

First-Quarter 2022 ResultsConsolidated revenue increased 1% to $117 million; excluding 2021 COVID-19 PCR testing revenue, consolidated revenue increased 3%Clinical Services revenue increased 2% to $99 million; excluding 2021 COVID-19 PCR testing revenue, Clinical Services revenue increased 4%Pharma Services revenue decreased 4% to $18 millionFORT MYERS, FL / ACCESSWIRE / April 27, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the " Company " ), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its first-quarter results for the period ended March 31, 2022."While our first quarter performance was disappointing and inconsiste

FT. MYERS, FL / ACCESSWIRE / April 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its first quarter 2022, financial results on Wednesday, April 27, 2022.The Company has scheduled a webcast and conference call to discuss their first quarter 2022 results on Wednesday, April 27, 2022 at 8:30 AM EDT. Interested investors should dial (888) 506-0062 (domestic) and (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 906928. A replay of the conference call will be available until 8:30 AM EDT on May 11

Recent Highlights:Full year 2021 consolidated revenue increased 9% year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 16%Fourth quarter consolidated revenue was flat year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 7%Inivata Limited, a wholly owned subsidiary of NeoGenomics ("Inivata"), received the CE mark for its RaDaR™ assay in January 2022 for the detection of molecular residual disease and recurrence and submitted to the MolDX program in the United States for the reimbursement of RaDaR™ for clinical testingFT. MYERS, FL / ACCESSWIRE / February 23, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading pr

FT MYERS, FL / ACCESSWIRE / February 2, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its fourth quarter 2021, financial results on Wednesday, February 23, 2022.The Company has scheduled a webcast and conference call to discuss their fourth quarter and full year 2021 results on Wednesday, February 23, 2022 at 8:30 AM EDT. Interested investors should dial (888) 506-0062 (domestic) and (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 501963. A replay of the conference call will be available unt

BEIJING, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited preliminary financial results for the third quarter ended September 30, 2021. Third Quarter and Recent Highlights Financials: Recorded total revenue of RMB 152.5 million (US $23.7 million) for the third quarter of 2021, representing a 36.2% increase over the same period of 2020 LDT revenue was RMB 93.0 million (US $14.4 million) in the third quarter of 2021, repr

Third-Quarter 2021 Results and Highlights:Consolidated revenue of $121 million, comprised of Clinical Services revenue of $102 million and Pharma Services revenue of $19 millionConsolidated revenue decreased 3% due to the discontinuation of prior year COVID-19 revenue; consolidated revenue increased 12% when excluding prior year COVID-19 revenueAnnounces plan to double its Clinical Services sales and medical affairs teams to further support RaDaR™ and drive the next phase of the Company's growthFT. MYERS, FL / ACCESSWIRE / November 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the " Company "), a leading provider of cancer-focused genetics testing services and global oncology contract research s

FT. MYERS, FL / ACCESSWIRE / October 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its third quarter 2021, financial results on Thursday, November 4, 2021.The Company has scheduled a webcast and conference call to discuss their third quarter results on Thursday, November 4, 2021 at 8:30 AM EDT. Interested investors should dial (888) 506-0062 (domestic) and (973) 528-0011 (international) at least five minutes prior to the call. A replay of the conference call will be available until 8:30 AM EDT on November 18, 2021, and can be accessed by dialing (877) 481-4010 (do

Second-Quarter 2021 Results and Highlights:Consolidated revenue increased 40% to $122 millionClinical Services revenue increased 37% to $101 millionPharma Services revenue increased 55% to $20 millionCompleted the acquisitions of Trapelo Health in April and Inivata Limited in JuneFORT MYERS, FL / ACCESSWIRE / August 6, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services, today announced its second-quarter results for the period ended June 30, 2021."Second-quarter results were strong as all three of our divisions grew significantly year-over-year. Importantly, our core cancer businesses showed meaningful signs of recovery as ou

Revenues of $17.8 million were driven by RT-PCR COVID-19 testing Initiated full commercial launch of CNSide™ cerebrospinal fluid assay for diagnosing and managing patients with metastatic cancer involving the central nervous system Received approximately 390,000 COVID-19 samples since June 2020 Hosted KOL webinar with leading neuro-oncologists discussing their use of CNSide and its importance in clinical decisions that affect patient outcomes Conference call begins at 4:30 p.m. Eastern time today Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2021 and provides